Literature DB >> 15694213

Improving depression outcomes in older adults with comorbid medical illness.

Linda H Harpole1, John W Williams, Maren K Olsen, Karen M Stechuchak, Eugene Oddone, Christopher M Callahan, Wayne J Katon, Elizabeth H Lin, Lydia M Grypma, Jürgen Unützer.   

Abstract

BACKGROUND: Depression is common in older adults and often coexists with multiple chronic diseases, which may complicate its diagnosis and treatment.
OBJECTIVE: To determine whether or not the presence of multiple comorbid medical illnesses affects patient response to a multidisciplinary depression treatment program. DESIGN, SETTING AND PARTICIPANTS: Preplanned analyses of Improving Mood-Promoting Access to Collaborative Treatment (IMPACT), a randomized controlled trial of 1801 depressed older adults (> or =60 years), which was performed at 18 primary care clinics from eight health care organizations in five states across the United States from July 1999 to August 2001. INTERVENTION: Intervention patients had access for up to 12 months to a depression care manager, supervised by a psychiatrist and a primary care expert, who offered education, care management and support of antidepressant management by the patient's primary care physician, or provided brief psychotherapy (Problem-Solving Treatment in Primary Care). MEASUREMENTS: Depression, quality of life (QOL; scale of 0-10) and mental health component score (MCS) of the Short-Form 12 assessed at baseline, 3, 6 and 12 months.
RESULTS: Patients suffered from an average of 3.8 chronic medical conditions. Although patients with more chronic medical conditions had higher depression severity at baseline, the number of chronic diseases did not affect the likelihood of response to the IMPACT intervention when compared to care as usual. Intervention patients experienced significantly lower depression during all follow-up time points as compared with patients in usual care independent of other comorbid illnesses (P<.001). Intervention patients were also more likely to experience substantial response (at least a 50% reduction in depressive symptoms) regardless of the number of comorbidities, to experience improved MCS-12 scores at 3 and 12 months, and to experience improved QOL.
CONCLUSIONS: The presence of multiple comorbid medical illnesses did not affect patient response to a multidisciplinary depression treatment program. The IMPACT collaborative care model was equally effective for depressed older adults with or without comorbid medical illnesses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694213     DOI: 10.1016/j.genhosppsych.2004.09.004

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  41 in total

1.  Self-reported discrimination and mental health status among African descendants, Mexican Americans, and other Latinos in the New Hampshire REACH 2010 Initiative: the added dimension of immigration.

Authors:  Gilbert C Gee; Andrew Ryan; David J Laflamme; Jeanie Holt
Journal:  Am J Public Health       Date:  2006-10       Impact factor: 9.308

Review 2.  Collaborative Care for Psychiatric Disorders in Older Adults: A Systematic Review.

Authors:  Pallavi Dham; Sarah Colman; Karen Saperson; Carrie McAiney; Lillian Lourenco; Nick Kates; Tarek K Rajji
Journal:  Can J Psychiatry       Date:  2017-07-18       Impact factor: 4.356

3.  Behavioral health services influence medical treatment utilization among primary care patients with comorbid substance use and depression.

Authors:  Benjamin I Felleman; Dylan R Athenour; Minhdan T Ta; David G Stewart
Journal:  J Clin Psychol Med Settings       Date:  2013-12

4.  Integrating depression and chronic disease care among patients with diabetes and/or coronary heart disease: the design of the TEAMcare study.

Authors:  Wayne Katon; Elizabeth H B Lin; Michael Von Korff; Paul Ciechanowski; Evette Ludman; Bessie Young; Carolyn Rutter; Malia Oliver; Mary McGregor
Journal:  Contemp Clin Trials       Date:  2010-03-27       Impact factor: 2.226

5.  Cardiovascular disease risk factors and psychological distress among Hispanics/Latinos: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

Authors:  Sheila F Castañeda; Christina Buelna; Rebeca Espinoza Giacinto; Linda C Gallo; Daniela Sotres-Alvarez; Patricia Gonzalez; Addie L Fortmann; Sylvia Wassertheil-Smoller; Marc D Gellman; Aida L Giachello; Gregory A Talavera
Journal:  Prev Med       Date:  2016-02-26       Impact factor: 4.018

6.  Long-Term Clinical Outcomes from a Randomized Controlled Trial of Two Implementation Strategies to Promote Collaborative Care Attendance in Community Practices.

Authors:  Amy M Kilbourne; David E Goodrich; Kristina M Nord; Celeste Van Poppelen; Julia Kyle; Mark S Bauer; Jeanette A Waxmonsky; Zongshan Lai; Hyungjin M Kim; Daniel Eisenberg; Marshall R Thomas
Journal:  Adm Policy Ment Health       Date:  2015-09

7.  Adaptations and patient responses to behavioral intervention components in a depression-focused chronic disease care model implemented in India.

Authors:  Leslie C M Johnson; Lydia Chwastiak; Subramani Poongothai; Nikhil Tandon; Ranjit Mohan Anjana; Sosale Aravind; Gumpeny Ramachandra Sridhar; Deepa Rao; Viswanathan Mohan; Mohammed K Ali
Journal:  Transl Behav Med       Date:  2020-02-03       Impact factor: 3.046

8.  Improving depression care in patients with diabetes and multiple complications.

Authors:  Leslie S Kinder; Wayne J Katon; Evette Ludman; Joan Russo; Greg Simon; Elizabeth H B Lin; Paul Ciechanowski; Michael Von Korff; Bessie Young
Journal:  J Gen Intern Med       Date:  2006-07-07       Impact factor: 5.128

Review 9.  Interventions for improving outcomes in patients with multimorbidity in primary care and community settings.

Authors:  Susan M Smith; Emma Wallace; Tom O'Dowd; Martin Fortin
Journal:  Cochrane Database Syst Rev       Date:  2016-03-14

10.  Augmentation treatment in major depressive disorder: focus on aripiprazole.

Authors:  J Craig Nelson; Andrei Pikalov; Robert M Berman
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.